Tag: KIT Exon 17/18
-
Bezuclastinib Peaks in GIST: Positive PEAK Phase 3 Results for KIT Exon 17/18 Mutants
New Phase 3 data positions Bezuclastinib as a potential new standard for KIT Exon 17/18 mutant GIST In a pivotal development for patients with advanced gastrointestinal stromal tumors (GISTs), Bezuclastinib demonstrated positive outcomes in the PEAK Phase 3 study focusing on KIT exon 17/18 mutant disease. GISTs are driven by complex mutations in the KIT…
-
Bezuclastinib Achieves Positive PEAK Phase 3 Results in Advanced GIST: A Potential New Standard for KIT Exon 17/18 Mutant Disease
Bezuclastinib Makes a Major Leap in KIT Exon 17/18 Mutant GIST Recent PEAK Phase 3 results are positioning Bezuclinib as a potentially practice-changing therapy for patients with advanced gastrointestinal stromal tumors (GIST) driven by KIT Exon 17/18 mutations. These mutations have long been associated with primary resistance to first-line therapies and later-line inhibitors, making the…